| [1] |
Yamashita A, Hayashi Y, Nemoto-Sasaki Y, et al. Acyltransferases and transacylases that determine the fatty acid composition of glycerolipids and the metabolism of bioactive lipid mediators in mammalian cells and model organisms[J]. Prog Lipid Res, 2014, 53:18-81. doi: 10.1016/j.plipres.2013.10.001.
pmid: 24125941
|
| [2] |
Huang Y, Wang Y, Wang Y, et al. LPCAT1 Promotes Cutaneous Squamous Cell Carcinoma via EGFR-Mediated Protein Kinase B/p38MAPK Signaling Pathways[J]. J Invest Dermatol, 2022, 142(2):303-313.e9. doi: 10.1016/j.jid.2021.07.163.
|
| [3] |
Ma L, Li DH, Xu Z. HECTD2 Represses Cell Proliferation in Colorectal Cancer through Driving Ubiquitination and Degradation of LPCAT1[J]. Mol Biol(Mosk), 2022, 56(4):574-584. doi: 10.31857/S0026898422040073.
|
| [4] |
Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3):229-263. doi: 10.3322/caac.21834.
|
| [5] |
Fei M, Zhang Y, Li H, et al. HIF-2α/LPCAT1 orchestrates the reprogramming of lipid metabolism in ccRCC by modulating the FBXW7-mediated ubiquitination of ACLY[J]. Int J Biol Sci, 2025, 21(2):614-631. doi: 10.7150/ijbs.103032.
pmid: 39781455
|
| [6] |
Li X, Li S, Li H, et al. Inhibition of recurrence and metastasis in triple-negative breast cancer through nanoparticle-mediated silencing of LPCAT1 to remodel ATP energy metabolism[J]. Sci China Life Sci, 2025, 68(7):1980-1995. doi: 10.1007/s11427-024-2887-x.
pmid: 40343577
|
| [7] |
Tao M, Luo J, Gu T, et al. LPCAT1 reprogramming cholesterol metabolism promotes the progression of esophageal squamous cell carcinoma[J]. Cell Death Dis, 2021, 12(9):845. doi: 10.1038/s41419-021-04132-6.
pmid: 34518524
|
| [8] |
Zhao H, Xiao Q, An Y, et al. Phospholipid metabolism and drug resistance in cancer[J]. Life Sci, 2025, 372:123626. doi: 10.1016/j.lfs.2025.123626.
|
| [9] |
Zhao Y, Liu Y, Shi X. LncRNA AC012360.1 facilitates growth and metastasis by regulating the miR-139-5p/LPCAT1 axis in hepatocellular carcinoma[J]. Environ Toxicol, 2023, 38(9):2192-2203. doi: 10.1002/tox.23856.
|
| [10] |
Wang B, Hu S, Teng Y, et al. Current advance of nanotechnology in diagnosis and treatment for malignant tumors[J]. Signal Transduct Target Ther, 2024, 9(1):200. doi: 10.1038/s41392-024-01889-y.
|
| [11] |
Xia C, Dong X, Li H, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants[J]. Chin Med J(Engl), 2022, 135(5):584-590. doi: 10.1097/CM9.0000000000002108.
|
| [12] |
陈韩, 杨江怡, 陈华, 等. 溶血磷脂酰胆碱酰基转移酶1在宫颈癌中的表达及临床意义[J]. 疑难病杂志, 2023, 22(10):1051-1055. doi: 10.3969/j.issn.1671-6450.2023.10.008.
|
| [13] |
时春丽, 周桂华, 陈炜, 等. 基于β-catenin/Slug信号通路表达探讨LPCAT1对子宫颈癌生物学行为的影响[J]. 临床与实验病理学杂志, 2024, 40(3):285-290. doi: 10.13315/j.cnki.cjcep.2024.03.012.
|
| [14] |
Gao F, Chen J, Zhang T, et al. LPCAT1 functions as an oncogene in cervical cancer through mediating JAK2/STAT3 signaling[J]. Exp Cell Res, 2022, 421(1):113360. doi: 10.1016/j.yexcr.2022.113360.
|
| [15] |
Wolde T, Huang J, Huang P, et al. Depleted-MLH1 Expression Predicts Prognosis and Immunotherapeutic Efficacy in Uterine Corpus Endometrial Cancer: An In Silico Approach[J] Bio Med Informatics, 2024, 4(1):326-346.
|
| [16] |
Wang Y, Liu Q, Sun Y, et al. Association between metabolic disorders and clinicopathologic features in endometrial cancer[J]. Front Endocrinol (Lausanne), 2024, 15:1351982. doi: 10.3389/fendo.2024.1351982.
|
| [17] |
Kulkarni A, Bowers LW. The role of immune dysfunction in obesity-associated cancer risk, progression, and metastasis[J]. Cell Mol Life Sci, 2021, 78(7):3423-3442. doi: 10.1007/s00018-020-03752-z.
pmid: 33464384
|
| [18] |
Crosbie EJ, Kitson SJ, McAlpine JN, et al. Endometrial cancer[J]. Lancet, 2022, 399(10333):1412-1428. doi: 10.1016/S0140-6736(22)00323-3.
pmid: 35397864
|
| [19] |
Goswami S, Zhang Q, Celik CE, et al. Dietary fat and lipid metabolism in the tumor microenvironment[J]. Biochim Biophys Acta Rev Cancer, 2023, 1878(6): 188984. doi: 10.1016/j.bbcan.2023.188984.
|
| [20] |
Zhao T, Sun R, Ma X, et al. Overexpression of LPCAT1 enhances endometrial cancer stemness and metastasis by changing lipid components and activating the TGF/β-Smad2/3 signaling pathway[J]. Acta Biochim Biophys Sin (Shanghai), 2022, 54(7):904-916. doi: 10.3724/abbs.2022076.
|
| [21] |
Lin X, Zheng J, Cai X, et al. Glycometabolism and lipid metabolism related genes predict the prognosis of endometrial carcinoma and their effects on tumor cells[J]. BMC Cancer, 2024, 24(1):571. doi: 10.1186/s12885-024-12327-1.
pmid: 38720279
|
| [22] |
Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022[J]. CA Cancer J Clin, 2022, 72(1):7-33. doi: 10.3322/caac.21708.
|
| [23] |
Tan R, Wen M, Yang W, et al. Integrated proteomics and scRNA-seq analyses of ovarian cancer reveal molecular subtype-associated cell landscapes and immunotherapy targets[J]. Br J Cancer, 2025, 132(1):111-125. doi: 10.1038/s41416-024-02894-2.
|
| [24] |
Nieman KM, Kenny HA, Penicka CV, et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth[J]. Nat Med, 2011, 17(11):1498-1503. doi: 10.1038/nm.2492.
pmid: 22037646
|
| [25] |
Duarte Mendes A, Freitas AR, Vicente R, et al. Adipocyte Microenvironment in Ovarian Cancer: A Critical Contributor?[J]. Int J Mol Sci, 2023, 24(23):16589. doi: 10.3390/ijms242316589.
|
| [26] |
Wu Y, Pu X, Wang X, et al. Reprogramming of lipid metabolism in the tumor microenvironment: a strategy for tumor immunotherapy[J]. Lipids Health Dis, 2024, 23(1):35. doi: 10.1186/s12944-024-02024-0.
pmid: 38302980
|
| [27] |
Wen F, Ling H, Ran R, et al. LPCAT3 regulates the proliferation and metastasis of serous ovarian cancer by modulating arachidonic acid[J]. Transl Oncol, 2025, 52:102256. doi: 10.1016/j.tranon.2024.102256.
|
| [28] |
Guo Y, Wei M, Fan J, et al. The Role and Mechanism of CircCOG5 in Regulating Ferroptosis in Ovarian Cancer Cells by Targeting miR-532-3p/LPCAT3[J]. Biochem Genet, 2026, 64(3):3367-3389. doi: 10.1007/s10528-025-11183-3.
|
| [29] |
Li Z, Hu Y, Zheng H, et al. LPCAT1-mediated membrane phospholipid remodelling promotes ferroptosis evasion and tumour growth[J]. Nat Cell Biol, 2024, 26(5):811-824. doi: 10.1038/s41556-024-01405-y.
|
| [30] |
Lee H, Zhuang L, Gan B. Rewiring cancer cell death: LPCAT1 shapes lipid composition and ferroptosis resistance[J]. Cell Death Differ, 2024, 31(9):1101-1103. doi: 10.1038/s41418-024-01364-9.
pmid: 39138374
|